# Case Report: A case of severe pulmonary hypertension combined with FBN1 mutation associated geleophysic dysplasia

## TL;DR

A patient with a rare genetic disorder and severe lung hypertension was treated, highlighting the need for early surgical intervention.

## Contribution

This case report provides new insights into managing pulmonary hypertension associated with FBN1 mutation-related geleophysic dysplasia.

## Key findings

- Treprostinil treatment reduced pulmonary artery pressure in the patient.
- Early surgical intervention for mitral valve pathology may improve prognosis in these patients.
- Mitral stenosis worsened despite successful valvuloplasty and atrial septal windowing.

## Abstract

FBN1 gene mutation-associated geleophysic dysplasia (GD) leads to the formation of complex and refractory pulmonary hypertension (PH) through a multifactorial combination of precapillary factors, postcapillary factors, and respiratory pathology. However, clinical experience regarding the diagnosis and management of these patients remains limited.

The patient was admitted to the hospital with severe PH symptom. He exhibited typical facial features, severe disproportionate short stature, and was diagnosed with GD following the identification of a heterozygous mutation in exon 42 of the FBN1 gene via whole-exome sequencing. Pulmonary artery pressure was reduced after admission and treatment with treprostinil, but mitral stenosis progressively worsened. The patient was then treated with mitral valvuloplasty + atrial septal windowing at an outside hospital, the procedure was successful, but the patient could not be weaned from ECMO after the procedure.

This case expands our understanding of therapeutic strategies for PH associated with FBN1 mutation–related GD. Treprostinil may be effective in the treatment of these patients. Given the risk of progressive pulmonary disease, early surgical intervention for mitral valve pathology may be crucial for improving prognosis.